Article Per Year (5 Year)
p-Index From 2021 - 2026
0.92
P-Index
This Author published in this journals
All Journal Medical Journal of Indonesia eJournal Kedokteran Indonesia Jurnal Penyakit Dalam Indonesia
Suzy Maria
Divisi Alergi Dan Imunologi, Kelompok Staf Medis Ilmu Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo, Jakarta
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
The Benefits of High-Dose Vitamin C in Patients with Sepsis: An Evidence-Based Case Report Mawin Mahen; Nabila Hasan; Suzy Maria
eJournal Kedokteran Indonesia Vol. 10 No. 2 - Agustus 2022
Publisher : Faculty of Medicine Universitas Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.23886/ejki.10.83.151-61

Abstract

In sepsis, there is an increase in oxidative stress which plays important role in further physiological derangement. Due to its potent antioxidant effect, vitamin C has been proposed as a potential adjunct treatment in patients with sepsis. This study aims to evaluate the benefits of vitamin C administration in patients with sepsis. A systematic search was conducted using electronic databases PubMed, Scopus, ProQuest, and Cochrane with keywords combination of vitamin C/ascorbic acid and sepsis/septic. The limits of the search included English language, human subjects, and adults. To limit the confounding effect, only studies with vitamin C monotherapy were considered for inclusion. Seven relevant studies comprising five clinical trials and two retrospective studies were included in this paper for critical appraisal. Most studies found some clinical benefits with the use of vitamin C in patients with sepsis compared to placebo, such as a reduction in SOFA score and mortality. However, these favourable outcomes were not consistent in all studies. In conclusion, vitamin C is a promising adjunct treatment option in patients with sepsis, however further large, optimized multicenter trials are needed to definitively confirm its benefits. Keywords: vitamin C, ascorbic acid, sepsis, septic shock.   Manfaat Vitamin C Dosis Tinggi untuk Pasien Sepsis Abstrak Kondisi sepsis menyebabkan peningkatan stres oksidatif yang berperan penting dalam menyebabkan gangguan fisiologis lebih lanjut. Karena memiliki efek antioksidan yang kuat, vitamin C telah diusulkan sebagai terapi adjuvan yang menjanjikan pada pasien sepsis. Penelitian ini bertujuan untuk mengevaluasi manfaat pemberian vitamin C pada pasien sepsis. Pencarian sistematis dilakukan menggunakan database elektronik PubMed, Scopus, ProQuest, dan Cochrane dengan kombinasi kata kunci vitamin C/asam askorbat dan sepsis/ septik. Batas pencarian yaitu bahasa Inggris, subjek manusia, dan usia dewasa. Untuk membatasi efek perancu, hanya studi yang menggunakan monoterapi vitamin C yang dipertimbangkan untuk dimasukkan. Tujuh studi relevan yang terdiri dari lima uji klinis dan dua studi retrospektif dimasukkan dalam tulisan ini untuk telaah kritis. Sebagian besar studi mendapatkan manfaat klinis penggunaan vitamin C pada pasien sepsis dibandingkan dengan plasebo, misalnya penurunan skor SOFA dan angka mortalitas, namun hasil positif ini tidak konsisten dalam semua penelitian. Sebagai kesimpulan, vitamin C adalah pilihan terapi adjuvan yang menjanjikan pada pasien sepsis, namun butuh penelitian multisenter yang lebih besar dan optimal untuk memastikan manfaatnya secara definitif. Kata kunci: vitamin C, asam askorbat, sepsis, syok sepsis
Mutation and Variant of Coronavirus Disease 2019 (COVID-19): Review of Current Literatures Susilo, Adityo; Jasirwan, Chyntia Olivia Maurine; Wafa, Syahidatul; Maria, Suzy; Rajabto, Wulyo; Muradi, Akhmadu; Fachriza, Ihza; Putri, Myranda Zahrah; Gabriella, Stacy
Jurnal Penyakit Dalam Indonesia Vol. 9, No. 1
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Since March 2020, the Coronavirus Disease 2019 (COVID-19) pandemic has engulfed the world, including Indonesia, for nearly two years. SARS-CoV-2 has undergone several mutations during its evolution as a pathogen, resulting in various variants of global concern. Variants of this virus are suspected to impede the outbreak resolution and possibly causing the outbreak to spiral out of control. There is still considerable debate and research underway regarding the new SARS-CoV-2 variants. Rapid transmission mechanisms and widespread vaccination coverage have accelerated the virus’s mutation rate and resulted in numerous new variants. To date, this has resulted in the discovery of a new variant Omicron (B.1.1.529) in November 2021 in South Africa, which has since spread to 103 countries. Omicron is designated a Variant of Concern (VoC) due to its more powerful transmission than the previous variant. Although some information indicates that the symptoms associated with this variant are typically mild, the rapid transmission of Omicron can increase the next wave of COVID-19 cases. Additional research is required to determine transmissibility, pathogenesis, diagnosis, and proper management. As a result, we conducted an adjunct to studies on various COVID-19 mutations and variants until January 2022.
Safety and immunogenicity of the CoV2-Bio in a healthy population aged 18 years and older in Indonesia Maria, Suzy; Olfriani, Ciho; Koesnoe, Sukamto; Sekartini, Rini; Soedjatmiko; Medise, Bernie Endyarni; Yuniar, Irene; Indawati, Wahyuni; Wirahmadi, Angga; Sari, Rini Mulia; Adi, Nuri Purwito; Retnaningdyah, Windri
Medical Journal of Indonesia Vol. 34 No. 1 (2025): March
Publisher : Faculty of Medicine Universitas Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.13181/mji.oa.247476

Abstract

BACKGROUND According to the WHO Target Product Profiles for COVID-19 Vaccines, vaccine development should be indicated for active immunization in all populations, in conjunction with other control measures to curtail the pandemic. Several RBD-based COVID-19 vaccines are being evaluated and have shown advantages. CoV2-Bio was developed based on the wild-type SARS-CoV-2 RBD amino acid sequence, representing residues of the spike protein of the Wuhan-Hu-1 isolate. This study aimed to evaluate the safety and immunogenicity of CoV2-Bio when compared to CoronaVac. METHODS This was an observer-blinded, randomized controlled prospective study of safety and immunogenicity of the CoV2-Bio in healthy adult population. A total of 54 healthy participants were randomized to receive either 3 doses of CoV2-Bio or 2 doses of CoronaVac, and 1 dose of placebo, administered 28 days apart. Participants were followed up for safety and immunogenicity. IgG antibody titers (ELISA) and neutralization assay against Wuhan and Delta strains were evaluated at baseline, Days 28, 56, and 84. We assessed seropositive rate, seroconversion, and GMT as parameters. RESULTS Both vaccines were well tolerated and induced good antibody response. The incidence rate and intensity of local and systemic adverse events did not differ between vaccine and control groups. The vaccine group showed a larger proportion of seroconversion (4-fold increase antibody) (87.5% versus 46.2%, p = 0.001) and higher GMT (305.9 AU/ml versus 102.4 AU/ml, p<0.001) when compared to control group. CONCLUSIONS 3 doses of the CoV2-Bio are safe and immunogenic in healthy adult population. 3 doses of the CoV2-Bio COVID-19 vaccine produce a better immunogenicity profile compared to CoronaVac.
Co-Authors Adityo Susilo, Adityo Baihaqi, Fahri Ahmad Bernie Endyarni Medise Chyntia Olivia Maurine Jasirwan, Chyntia Olivia Maurine Fachriza, Ihza Gabriella, Stacy Ihza Fachriza Irene Yuniar, Irene Magdalena, Bellinda Mawin Mahen Muradi, Akhmadu Myranda Zahrah Putri Nabila Hasan Nuri Purwito Adi Olfriani, Ciho Putri, Myranda Zahrah Retnaningdyah, Windri Rini Mulia Sari Rini Sekartini Soedjatmiko Stacy Gabriella Sukamto Koesnoe Syahidatul Wafa Syahidatul Wafa, Syahidatul Wahyuni Indawati, Wahyuni Wirahmadi, Angga Wulyo Rajabto